Global Advances In Health And Medicine Launches Global Media Platform To Support An Evolving Health Care System

— New Leadership and Editorial Management Team Established

BOSTON, Jan. 15, 2015 /PRNewswire/ — Global Advances in Health and Medicine (GAHM) announced today the launch of their new global multi-media publishing platform and a newly appointed interdisciplinary editorial leadership team. GAHM’s new platform serves as a breaking and scientific news resource for health, business and community leaders and patients who are dedicated to improving health and well-being through a whole-person and whole-systems approach to care.

GAHM’s unique publishing platform includes a peer-reviewed, indexed medical journal that provides original research articles, as well as multiple online forums that encourage breakthrough thinking, innovation, and analysis of policy initiatives, including a dynamic editor’s blog, a news blog dedicated to global integration of information, and an enhanced user experience. GAHM publishes its journal six times per year in print, digital and mobile formats, with abstracts in three different languages (English, Spanish, Chinese). Research and perspective articles are focused on diverse therapeutic and healing traditions and systems, including conventional biomedicine, integrative medicine, traditional Chinese medicine and other integrative therapies, such as art and music therapy, and reach readers in more than 40 countries.

“Our task is to build on the strong base we’ve developed during these past three years, as we believe now is the time to accelerate change towards innovative whole-person and whole-system approaches to health. The launch of our new publishing platform will help us build further on the growing global network of health care providers, researchers, clinicians, health policy experts and consumers that we’ve established,” explained Michele Mittelman, RN, MPH, founder and chief executive officer, GAHM.

GAHM was originally created in 2011. Since then, the natural integration of whole-systems care into the mainstream health care model, coupled with a growing use of technology for global sharing of information, has served as a driving force in the expansion of GAHM from an online medical journal to a comprehensive, global multimedia publishing platform.

GAHM’s editorial leadership is headed by a nationally and internationally recognized interdisciplinary team of innovators in the field of whole-person care:

Mary Jo Kreitzer, PhD, RN, FAAN, co-editor-in-chief of GAHM, is founder and director of the Center for Spirituality & Healing at the University of Minnesota. In addition to her roles as nurse, teacher, healthcare administrator and researcher, she is an internationally recognized pioneer and expert in the field of integrative health and well-being.

Robert Saper, MD, MPH, co-editor-in-chief of GAHM, is director of The Program for Integrative Medicine and Health Care Disparities at Boston Medical Center and associate professor of Family Medicine at Boston University School of Medicine. He has more than 25 years of experience integrating evidence-based complementary therapies such as yoga massage and relaxation techniques with conventional medicine.

This team has collectively established a streamlined, swift and scientifically rigorous peer-review and editorial process that will produce a breadth of usefully indexed content for GAHM in support of whole-systems care.

About Global Advances in Health and Medicine

Global Advances in Health and Medicine (GAHM) is a modern, global multimedia platform that combines original research with breakthrough thinking and analysis of policy initiatives to catalyze global conversations, collaboration and the building of communities to advance whole-person and whole-systems approaches to health care. GAHM’s platform includes an online and in print, peer-reviewed, indexed, medical journal published six times per year in three languages, and an interactive website that reaches readers in more than 40 countries.

AMRI Announces CFO Transition

ALBANY, New York, Jan. 12, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) today announced that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Mr. Nolan will remain with AMRI through February 2015 to support an orderly transition.

The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015.

“We appreciate Mike’s contributions to AMRI’s growth, and I know I speak for the management team and Board of Directors in wishing him success with his future endeavors,” said William S. Marth, AMRI’s President and Chief Executive Officer.

“I am pleased that Felicia will be joining the AMRI team at this important time for the company,” continued Mr. Marth. “As we continue to build and integrate our business, Felicia’s strong track record of building global finance infrastructures and teams will be a tremendous addition to AMRI.”

Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ladin has spent the majority of her career in the pharmaceutical industry, most recently as Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA. Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Teva’s financial planning and analysis operations, and from 2002 to 2008 was tax director for the U.S. During her 12 year tenure at Teva, Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division’s growth into an $8 billion global business.

The company intends to release its fourth quarter and full year 2014 financial results and 2015 guidance, including the most recent acquisitions, in February 2015.

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

Hard Rock International Hires Daniel Cheng As Senior Vice President Development, Asia-Pacific


ORLANDO, Florida, Jan. 5, 2015 /PRNewswire/ — Hard Rock International – owner of one of the world’s most-recognizable and iconic brands – announces the hiring of Daniel Cheng as SVP of Business Development, Asia-Pacific. Cheng’s appointment is a strategic move designed to accelerate momentum behind the brand’s global gaming growth plans. Cheng will be responsible for identifying the appropriate casino investment and development partners within key countries, such as Japan, Korea, Vietnam and the Philippines.



“Cheng’s experience and strengths complement our company’s development needs and we’re looking forward to further growing the brand’s Asian footprint under his guidance,” says Hamish Dodds, chief executive officer of Hard Rock International.

Bringing nearly three decades of multiple industry experiences, Cheng’s past gaming experience includes development roles with Bally Gaming Systems, consulting with the Government of Singapore and most recently, Resorts World Inc. – the international resort development, Internet gaming and brand licensing business entity of the Genting Group. Cheng will be based out of Singapore.

Internationally recognized as a world-class entertainment and lifestyle brand, Hard Rock properties offer stylish and contemporary design, unparalleled service and the thread that unites them all – music. Hard Rock’s portfolio of Hotels and Casinos are located in the world’s most enviable resort destinations, as well as urban gateway cities. For more information or to book a stay at any of the Hard Rock Hotels & Casinos, please visit

About Hard Rock International

With a total of 194 venues in 60 countries, including 148 cafes, 21 hotels and 10 casinos, Hard Rock International (HRI) is one of the most globally recognized companies. Beginning with an Eric Clapton guitar, Hard Rock owns the world’s greatest collection of music memorabilia, which is displayed at its locations around the globe. Hard Rock is also known for its collectible fashion and music-related merchandise, Hard Rock Live performance venues and an award-winning website. HRI owns the global trademark for all Hard Rock brands. The company owns, operates and franchises Cafes in iconic cities including London, New York, San Francisco, Sydney and Dubai. HRI also owns, licenses and/or manages hotel/casino properties worldwide. Destinations include the company’s two most successful Hotel and Casino properties in Tampa and Hollywood, Fl., both owned and operated by HRI parent company The Seminole Tribe of Florida, as well as other exciting locations including Bali, Biloxi, Chicago, Cancun, Ibiza, Las Vegas, Macau and San Diego. Upcoming new Hard Rock Cafe locations include San Juan, Asuncion and Auckland. New Hard Rock Hotel projects include Daytona Beach, Dubai, Los Cabos, Dallas-Fort Worth, Abu Dhabi, and Shenzhen and Haikou in China. For more information on Hard Rock International, visit

For More Media Information:
Jill Chandler/ Daniella DelaOsa /
Jacqueline De La Espriella
The Zimmerman Agency +1.850.668.2222

Photo –

BioNet Strengthens Advisory Board with Appointment of Vaccine Veteran Jacques-Francois Martin

BioNet-Asia appoints Jacques-Francois Martin to its advisory board as it moves its Recombinant Pertussis vaccine into Phase II/III.

LYON, France, Dec. 19, 2014 /PRNewswire/ — BioNet-Asia (BioNet), a vaccine company focused on innovative vaccine discovery and supply, announced that vaccine senior executive Jacques-Francois Martin was joining its Advisory Board effective January 1st.

Logo –

“Jacques-Francois is a highly respected executive in the world of vaccine and evidence of the commercial successes he has led are too many to mention.  I am glad that BioNet will benefit from his tremendous experience and knowledge, and I am personally looking forward to working with him again” said Pham Hong Thai, BioNet-Asia CEO.

Martin has spent a lifetime in the pharmaceutical and biotech industries. He is the founder and CEO of Parteurop Pharma, a French consulting firm and has been board member of several life sciences companies and organizations such as the International AIDS Vaccine Initiative. He was also the CEO of Pasteur Merieux Connaught (now Sanofi-Pasteur) and Biocine (now part of Novartis Vaccines) before becoming President and CEO of The Vaccine Fund, an organization working together with GAVI (Global Alliance for Vaccines and Immunization) to provide life saving vaccines to low-income countries.

“I am delighted to join BioNet’s Advisory Board in such an exciting time for the company.  BioNet is uniquely positioned to develop and bring to market innovative and cost-effective vaccines to the developing world.  BioNet’s recombinant acellular pertussis is one of the most promising vaccines in its class and I am really looking forward to helping to develop the partnerships required to deliver such life-saving vaccines to the neediest,” said Martin.

For nearly ten years, BioNet has been working on the development of a new Recombinant Pertussis (RP) vaccine which has recently shown to be safe and immunogenic in humans. BioNet proprietary genetically-engineered non-toxic Pertussis Toxin induces a higher level of neutralizing antibody than conventional vaccines, and thus it could enhance a better protective immunity against pertussis which currently wanes rapidly with some acellular pertussis vaccines.

About BioNet-Asia

BioNet-Asia is an independent vaccine company with a focus on technological innovation and product supply. BioNet has a successful track record in product development partnership, technology transfer and global market access. In its manufacturing plant in Thailand, BioNet has a broad pipeline of vaccines in R&D and clinical stages, such as Recombinant Pertussis and combined vaccines. Bionet has transferred its Hib meningitis vaccine technology for the manufacturing of a full liquid pentavalent vaccine, and it has recently entered into a production partnership for producing a new Rabies vaccine. BioNet has also built several strategic alliances fostering vaccine self-reliance and leading to the production and supply of billions of doses of vaccines worldwide.

For further information, please contact:

BioNet-Asia Co., Ltd.
Mr. Supachai Nampornchaisakul
Tel: +66-2361-8110


Kinex Pharmaceuticals Appoints Chief Operating Officer

HONG KONG and BUFFALO, New York, Dec. 17, 2014 /PRNewswire/ — Kinex Pharmaceuticals announced today that Mr. Flint Besecker has been appointed Chief Operating Officer of the company. Mr. Besecker will have additional responsibility over Kinex’s emerging global operating platforms in addition to all corporate business matters reporting to Kinex’s Chief Executive Officer, Dr. Johnson Lau. More recently, Flint served as Chief Business Officer and has been Executive Vice-President and Chief Financial Officer of Kinex since July 2013 and a Board member since 2011.

Mr. Besecker’s expanded role underscores Kinex’s business strategy to continue expanding its global footprint with existing operations in the United States and in Asia. “Flint has contributed significantly to the business, strategic and operational development of Kinex since joining the Executive rank. His prior Fortune 500 execution experience along with capital market and global experience will be important for our long term global growth strategy.” Dr. Lau said. “We are delighted to have his commitment to further expand his role, and his depth of experience will contribute to our commitments to build value for shareholders.”

Mr. Michael Murphy, Chairman of Corporate Governance and Nominating Committee, stated, “Flint brings a wealth of operational experience to the company, and he complements the management team very well. The Board is confident that the management team, with Flint in his new role, will continue driving the company’s core business to success, including our ongoing global expansion.”

In accepting his appointment as the Chief Operating Officer, Mr. Besecker stated, “I believe we have an enormous market opportunity across multiple continents to positively influence next generation cancer treatment for patients. We have a strong oncology drug pipeline and an operational strategy to drive this global change and increase access to care. I am excited to support the vision of the leadership team and assist the company to evolve as a global oncology specialty pharmaceutical company.”

Mr. Besecker is a 20-year veteran of the healthcare industry, bringing a wealth of executive experience in all facets of healthcare. Some of his previous roles included CEO of the Center for Hospice and Palliative Care, Founder and Board Chair of Care Investment Trust, founder and President of CIT Healthcare, Managing Director of GE Healthcare Financial Services and Chief Risk Officer of Heller Healthcare. He has also held numerous Board positions in both private and public healthcare companies and is a former CPA in New York State.


AposTherapy Completes New Financing; Announces Global Expansion Initiatives

– Names Dr. David Levy, Donald Almeida, Dr. Michael Stocker, Rt Hon Alan Milburn To Expanded Board

NEW YORK, Dec. 3, 2014 /PRNewswire/ — AposTherapy announced that it has completed a new round of financing and is launching a global initiative to offer its technology and treatment through premier physical therapy centers and orthopedics practices. To date, the company has provided drug-free and surgery-free treatment to over 50,000 patients worldwide who suffer from osteoarthritis of the knee.

The company also announced an expanded Board of Directors, whose members include some of the most accomplished leaders in medicine, managed care, public health and healthcare consulting.

AposTherapy CEO Dr. David Levy, who joined the company in August, made the announcements. Dr. Levy is leading the initiative to transform AposTherapy from operators of company-owned and company-run clinics to providers of technology and training for established healthcare centers, “enabling us to operate more efficiently, grow more rapidly and to bring AposTherapy to so many more osteoarthritis patients seeking increased mobility and relief from pain.”

The Board of Directors, representing both Series A and Series B investors, comprises:

  • Dr. Avi Elbaz, an orthopedic surgeon and Dr. Amit Mor, M.D., AposTherapy founders.
  • Dr. David Levy, former Principal and leader of the PriceWaterhouseCoopers (PwC) global healthcare practice, founder of Franklin Health Inc., one of the nation’s first care management companies, and a primary care physician.
  • Ruti Alon, General Partner of Pitango General Capital, an expert in high-tech medical and life sciences startups.
  • Donald V. Almeida, former Vice Chairman of PwC Global, where he led its Global Markets and Industries program, including the healthcare, pharmaceutical, life sciences and government practices.
  • Dr. Michael Stocker, former President and CEO of Empire Blue Cross Blue Shield of New York, former Chairman of the New York City Health and Hospitals Corporation and former president of CIGNA Health Plans.
  • Rt Hon Alan Milburn, former Secretary of State for Health for the United Kingdom and Member of the U.K. Parliament from 1992-2010.

AposTherapy is a 10-year-old company, founded in Israel. Its therapy centers on a computerized analysis of a patient’s gait, and prescription of a personalized, patent-protected shoe-like medical device that patients wear for a short time each day to bring the body into optimal alignment and retrain the muscles to adopt a healthier walking pattern for lasting pain relief and improved mobility. Many patients facing knee replacements have been able to postpone or, in some cases, avoid surgery by using AposTherapy.

Dr. Levy said, “As an adjunct to surgical procedures, AposTherapy is an important tool in the treatment of osteoarthritis. In addition to its therapeutic benefits, AposTherapy can reduce some of the financial burden on the health care system.”

In the U.K. and Singapore, where the company runs its own clinics, it has also been executing its new strategy for the past two months. It has appointed leading physical therapy centers in London, Birmingham, Manchester, and Southampton, including Physio 1st, Premier Physical Healthcare, and former Olympics Physiotherapist Kim Waters’ Therapeutics Southampton. In Singapore, it has appointed Core Concepts, that country’s largest private physiotherapy group in that country.

In the U.S., where it has operated a clinic in Manhattan for the past year, AposTherapy has appointed its first providers — in Manhattan, Long Island, Westchester and Putnam Counties. The first U.S. provider, One Physical Therapy in Syosset NY, reports that it has treated some 40 patients since August, with all of them reporting positive results to date. Dr. Levy said that the company plans to expand to additional markets here.

AposTherapy was founded in 2004 in Israel by Dr. Elbaz and Dr. Mor, the company’s Chairman and Vice Chairman, respectively. The company operates three of its own centers in Israel. “Not a day passes,” Dr. Levy said, “that I don’t reflect on the genius of our founders, Avi and Amit, whose vision and persistence got us where we are, and on the amazing team they have assembled to help get us there. We are entering a new phase of growth and achievement, and I am truly grateful and excited to be part of this journey.”

Institut Pasteur Appoints Isabelle Buckle, EVP, Research Applications and Industrial Partnerships and Pierre Legrain, EVP, Academic Development & Grant Office to Reinforce its Partnership Strategy Between Academia and Private Industry.

PARIS, Dec. 1, 2014 /PRNewswire/ — Institut Pasteur, research institute of excellence in science, medicine and public health since 1887, and a network of 32 Institut Pasteur worldwide, announces the appointment of Dr. Isabelle Buckle, as Executive-Vice President Research Applications and Industrial Partnerships Department and Dr. Pierre Legrain, as Executive Vice-President, Academic Development and Grant Office Direction. These two strategic positions were created to strengthen the links between Institut Pasteur research, academia and private industry. These partnerships will support innovation in international research and education to advance science, medicine and health for the future.

Dr. Isabelle Buckle, PhD in Microbiology, has 25 years of international scientific, commercial and business experience in biotechnology, forged from her previous roles as Global Vice President Clinical Mass Spectrometry at Bruker Daltonics; CEO of InGen Biosciences (an In Vitro Diagnostics company); Worldwide Business Development Director for Global Big Pharmas accounts at Life Technologies, now part of Thermo Fisher Scientific and Regional Director in charge of European Diagnostic partnerships at Ciphergen Biosystems. Dr Buckle started her carrier at Pharmacia Biotech, now part of GE.

Dr. Buckle, in her new role at the Institut Pasteur, aims to develop an ambitious, reinforced cooperation with industrial and institutional partners, both in France and internationally, in close working relationships with Institut Pasteur Development and the international Institut Pasteur network. Her goal is to improve the cooperation process to leverage the value of patent-protected inventions accomplished by scientific teams at the Institut Pasteur, on campus or worldwide and support the ambitious entrepreneurship of new companies that exploit the scientific and technological know-how on campus.

Dr. Pierre Legrain, PhD in Genetics, has published over 80 scientific articles and has a solid research and management background. Recently he had the responsibility of Master and PhD students at the Graduate School of Ecole Polytechnique. Until 2012, he coordinated the evaluation of public research in the life sciences at AERES. He joined the CEA (French Alternative Energies and Atomic Energy Commission) in 2003 at the Direction of Biology Department of Joliot-Curie and, later on, managed the CEA Life Sciences Division. Pierre started as Laboratory Director at Institut Pasteur in 1995, where he created and managed the first start-up: Hybrigenics.

Dr Legrain’s key role at the newly created Academic Development and Grant Office Department is to foster the development of transversal research programs, some of which concern major human health areas, such as vaccinology, microbiology, oncology and brain science. These programs will involve both Institut Pasteur Campus teams and the entire Institut Pasteur international network. In the initial stages, these programs may be self-financed but they should attract new funding partners in subsequent phases.

The Academic Development and Grant Office Direction will work in close relationship with the  Research Applications and Industrial Partnerships Direction and with the Communication Direction to identify Institut Pasteur future partnerships with French and foreign public funding agencies, industry and private foundations.

“Dr. Buckle and Dr. Legrain both have excellent educational and management credentials to ensure the future growth of International Institut Pasteur and to support its research, education and public Health missions,” said Christian Brechot, President of Institut Pasteur. “We are happy that Isabelle and Pierre have joined us to develop the value of our scientific research with academic and industrial partnerships that is crucial to allow, on the one hand, patients to benefit from our campus and international network innovations and, on the other hand, to fund our research, in the interest of all.”

About the Institut Pasteur

For the past 125 years, scientists from the Institut Pasteur have been on the front line in the fight against major public health challenges worldwide, battling threatening human diseases. While leading the field of infectious diseases, pioneering teams at the Institut Pasteur are also recognized for their excellence in neuroscience, developmental biology, genetics and genomics. Their research efforts have lead to improvements in our understanding of living beings and to the development of new methods for the diagnosis, prevention and treatment of disease. The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics, promoting interdisciplinary and multidisciplinary cooperation, and transferring scientific discoveries to applications. To gain new victories in the fight against disease, Institut Pasteur teams have access to all the technological resources they need, to speed up and further improve the quality of their outstanding research.

With an international network of 32 institutes worldwide, the Institut Pasteur plays a key role in the understanding, prevention and fight against a vast number of diseases, particularly infectious diseases. Additionally, the Institut Pasteur works in collaboration with major international players to further progress in the life sciences.

The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their knowledge or top up their degree programs.

The Institut Pasteur’s budget relies on funding from four sources: donation, government contributions, business development and research contracts.

Press Contact:
Christine Phan, Institut Pasteur
Tel: +33(0)1-45-68-81-92

Government Affairs Expert Joins Heidrick & Struggles’ Life Sciences Practice In China

SHANGHAI, Dec. 1, 2014 /PRNewswire/ — Jonathan Zhu has joined Heidrick & Struggles (Nasdaq:HSII), a premier provider of Executive Search, Leadership Consulting and Culture Shaping services worldwide, as Partner within the Global Life Sciences & Government Affairs Practices, based in Shanghai, China.

Zhu has accumulated more than 20 years of professional experience gained in both the private and public sectors. He was one of the first Chinese-American lobbyists working for an established Washington, D.C.-based government affairs consulting firm. During his tenure with the organization, Zhu advised multinational companies in Sino-America transactions and business development at both the strategic and tactical levels.

“We are excited Jonathan is joining our firm,” said Charlie Moore, Global Practice Managing Partner of the firm’s Life Sciences Practice. “His extensive experience in the Life Sciences sector, coupled with his expertise and knowledge in Government Affairs and Executive Search, will make him an exceptional addition to our team, one who can bring immediate value to our multinational Life Sciences clients in China.”

Zhu held senior positions such as China Country General Manager and Corporate Marketing Director for both U.S. and Japanese publicly listed multinational companies in the Industrial and Analytical Medical Diagnostic industries. Prior to joining Heidrick & Struggles, Zhu was a Partner with another global executive search company where he led the Life Science & Government Affairs practices in China.

“Jonathan’s know-how and experience in Government Relations will also help multinationals operating in China effectively navigate in this heavily-regulated and highly competitive marketplace where policies and regulations are changing constantly,” Moore added.

Early in his career, Zhu worked for U.S. Department of Defense — reporting to a Major General in the U.S. Air Force where he gained the fundamental life values of devotion, discipline and teamwork. He also served on Asia Advisory Board for Coloplast, a Danish-based global medical device company. He has also served as advisor to several leading pharmaceutical and medical devices companies in the region.

Born in China and educated in the U.S. from high school, Zhu’s academic background includes an Engineering (B.S) from University of Maryland, Business (MBA) from University of Baltimore and Law (LL.M) from China University of Political Science & Law.

About Heidrick & Struggles:
Heidrick & Struggles (NASDAQ: HSII) is a premier provider of senior-level Executive Search, Culture Shaping and Leadership Consulting services. For more than 60 years, we have helped our clients build strong leadership teams through quality service, deep insights and our relationships with talented individuals worldwide. Today, Heidrick & Struggles’ leadership experts operate from principal business centers in North America, Latin America, Europe, Asia Pacific, Africa and the Middle East. For more information about Heidrick & Struggles, please visit

Media Contact: Karen Lau
+852 2103 9329

Photo –
Logo –

Nopras Technologies Inc. Appoints Director Of Business Development – East Coast Operations

NOVI, Mich., Nov. 18, 2014 /PRNewswire/ Nopras Technologies ( has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development – East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg’s corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.

Logo –

“We are pleased to welcome Stewart to this new position,” said Carla Glaze, Nopras Technologies’ Director of Strategic Accounts. “With a keen understanding of complex technical issues and an in-depth knowledge of statistical methods, both of which complement his business development experience in the CRO business segment, Stewart allows us to bring the highest level of sophistication, sensitivity, and timeliness to the needs of our Clients and future prospects, from the earliest stage of the new business development cycle. His unique background allows Nopras to further differentiate ourselves in the value proposition, as the CRO industry undergoes continual refinement geared to customer needs.” Rosenberg currently is completing 2014 academic appointments with the Department of Chemistry at The University of Connecticut, where he teaches chemistry, as well as an appointment at Central Connecticut State University, which he will continue in 2015, where he currently lectures in Inferential Statistics, addressing hypothesis testing, linear and multiple regression, ANOVA, and nonparametric methods.

“Stewart’s solid broad-based experience in new business development, as well as his innate grasp and continual assessment of the needs, opportunities and complexities facing global multinational companies, all of which he has nurtured over the past 35 years through project management, business development, licensing, and partnership relationships, allow Nopras to further execute on its mission,” said Ms. Glaze. “Nopras operates at the intersection of smaller CROs as well as larger consulting services, capitalizing on the strengths of each, by providing the advantage of flexibility and rapid decision-making seen in the former, as well as providing a focus on “high-end” complex global projects, more often seen in the latter. We are pleased to welcome Stewart to our team.”

Mr. Rosenberg has two sons and resides in Madison, CT with his wife Natalie, as well as with Bonnie, a one year rescued dachshund that was found abandoned on the streets of Hartford pregnant with two puppies, and which they adopted in February.

Nopras Technologies, Inc. is a global management consulting firm which specializes in CRO services to organizations in the pharmaceutical, biotechnology and biologics industries, as well as the medical device and diagnostics’ sectors. With core competencies in the life sciences’ technical services, process and organizational excellence, regulatory compliance, quality management, and product development, Nopras Technologies draws heavily upon the expertise and skills of uniquely qualified former FDA key personnel, as Nopras’ project Consultants, providing a tailored differentiation to Nopras’ operations and requests for services. Nopras Technologies has its headquarters in Novi, MI US and additional offices in Fort Washington, PA US; Singapore; and Shanghai.

Certain statements in this press release constitute forward-looking statements, are not historical facts, and involve risks and uncertainties that could cause actual results to differ from those expected and projected. Such risks and uncertainties include, but are not limited to (i) general economic conditions; (ii) conditions specific to the industry; (iii) the company’s’ ability to develop or acquire new technology or products through licensing, merger or acquisition and to obtain regulatory approval to commercialize diagnostic, therapeutic or preventative products; (iv) the effectiveness and ultimate market acceptance of any such products; (v) limitations on third party reimbursements with respect to any such products; and (vi) competition. The company does not undertake to update or revise any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

CVBT Update

LAS VEGAS, Nov. 6, 2014 /PRNewswire/ — CardioVascular BioTherapeutics, Inc. (“CVBT” or the “Company”) announced that on September 16, 2014, the Delaware Vice Chancellor signed a Final Order upholding the Company’s shareholder vote to replace the existing directors of the Company with Calvin A. Wallen III, Jon S. Ross Esq., Mickael A. Flaa, Grant Gordon, Robert (Wayne) Blackburn, James R. Richards, Robert W. Schleizer and Alfred C. Moran

Upon notification of the Final Order, a meeting of the new CVBT Board of Directors was held, at which Calvin A. Wallen III was appointed Chairman, Mickael A. Flaa was appointed President and CFO, and Jon S. Ross Esq. was appointed Secretary.

Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik were removed from all positions, committees and involvement in CVBT.  They no longer have any authority to act on behalf of CVBT or to access Company property or Company confidential information and the Company intends to take all necessary action to enforce such restrictions.

Prior to the entry of the Final Order, the Company was undercapitalized for several years and under a Status Quo Order for approximately 13 months.  The Status Quo Order is now lifted and the new Board of Directors and Management are working diligently to put the Company back on track after years of inactivity.  This will take time, commitment and sacrifice but the Board of Directors has adopted a plan, which Management is in the process of implementing, to (1) restructure and recapitalize the Company, (2) initiate manufacturing of CVBT’s active pharmaceutical ingredient, (3) clarify the regulatory pathway with the FDA for CVBT’s Chronic Diabetic Foot Ulcer clinical program and CVBT’s Treatment of Severe Coronary Heart Disease clinical program, and (4) take the Company public again.

The new Board of Directors appreciates the support from the shareholders and understands the desire for updates and news. While the new Board of Directors intends to report on “Results That Matter,” please understand that it will take time to rebuild CVBT and currently there is much to be done.

About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates for diseases characterized by inadequate blood flow to tissue or organs. The Company is the sponsor of a currently paused Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, access to capital, cash usage and financial performance.

Media Contact:
Corey M. Flaa
CardioVascular BioTherapeutics, Inc.